Clinical Trial

REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts

Study acronym: REPERFUSE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The main objective is to evaluate the efficacy of IV administration of the P2Y12 inhibitor (cangrelor) in addition to mecanich thrombectomy and WMD versus mecanich thrombectomy and WMD alone on the functional prognosis at 3 months, in patients with acute ischemic stroke eligible for mecanich thrombectomy on the basis of infusion imaging between 0 and 24 hours after the onset of symptoms.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-12-09; most recent amendment 2026-02-27.
Status change: Not Yet Recruiting → Recruiting 2022-03-11
Trial Details
NCT Number NCT04667078
Lead Sponsor Fondation Ophtalmologique Adolphe de Rothschild
Collaborators: Ministry of Health, France
Conditions Acute Ischemia
Enrollment 368 participants
Start Date 2022-03-02
Primary Completion 2030-03-01 (estimated)
Study Completion 2030-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-02